Navigation Links
The Hamner Institutes and Oslo Cancer Cluster Announce Partnership

RESEARCH TRIANGLE PARK, N.C. and OSLO, Feb. 18 /PRNewswire/ -- The Hamner Institutes at Research Triangle Park has signed a formal Memorandum of Understanding with the Oslo Cancer Cluster in Oslo, Norway, one of the leading cancer clusters in Europe. The goal of the collaboration is to strengthen The Hamner's Global BioScience Gateway for Translational Research and Business Development, which began with partnerships in China.  Through its partnership with the Oslo Cancer Cluster, the expanded Global Biosciences Gateway will now enable companies and comprehensive cancer centers to speed development of new cancer therapies.  The collaboration will create an infrastructure in North Carolina and Oslo for efficient drug discovery, high quality oncology clinical trials, and access to drug safety and regulatory experts that can address FDA, EMEA and eventually the Chinese SFDA.

Specific initiatives of The Hamner-Oslo collaboration will focus on translational research, business development, and training and education.  The Hamner will provide access to its wide network of research collaborators including three Comprehensive Cancer Centers located in North Carolina, the Shanghai Center for Disease Control, and Tianjin Institute for Hematology.  Training and education will include post-doctoral training in innovative drug safety technologies, business training for entering the U.S. market, and regulatory training for compliance with FDA standards. Oslo will bring its highly regarded research and Phase I resources, and potential future access to its own growing European network of collaborators, which includes Heidelberg, Lund, Toulouse, Barcelona and Madrid.  

Additionally, The Hamner Accelerator will facilitate the launch of Norwegian bioscience companies – currently numbering among some of the leading innovators in Europe entering the U.S. market.  The trilateral collaboration among The Hamner, the Oslo Cancer Cluster and China will serve as a vital portal for the pharmaceutical industry to access new discoveries and resources in oncology.

"We passionately believe that this partnership with The Hamner will enable companies and comprehensive cancer centers to speed development of new cancer therapies through global partnerships," said Bjarte Reve, CEO of the Oslo Cancer Cluster. "Over the last few years, we have already taken great strides in Europe to bring together such clusters, with concrete results, such as a Phase 1 network and joint EU-IMI submissions. This partnership with The Hamner is a logical next step to forge stronger links with the U.S. and also to complement our existing initiatives in China."

"The partnership with the Oslo Cancer Cluster, a world leader in cancer research and technology development, is a key link in a shared Global Biosciences Gateway and strategy to accelerate the development of new cancer therapeutics worldwide," said William Greenlee, CEO of The Hamner. "The ability we now have to identify and capture cutting-edge cancer research in Europe and China will not only benefit patients, but also will be an important driver for business and economic development in our respective countries."


The Hamner Institutes for Health Sciences is strategically located on a 56-acre campus in the heart of Research Triangle Park, N.C.  As a cross-disciplinary nonprofit organization, The Hamner Institutes acts as a catalyst to facilitate technology development among North Carolina universities, while serving as a gateway to establish research collaborations with the bio/pharmaceutical industry and countries in Europe and Asia.  The Hamner Institutes also has an Accelerator to support emerging companies and a new Institute for Translational Medicine to enhance its research in oncology, diabetes, and respiratory diseases.


Oslo Cancer Cluster NCE is a biotech cluster organization that is committed to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines. The cluster gained the status of Norwegian Centre of Expertise in 2007, and long term governmental co-funding. The cluster builds on Norway's unique infrastructure, from biobanks to extensive patient registries, that accelerates translational cancer research. In June 2008, Genome Technology named Oslo (along with North Carolina) as one of the 20 best places for biotech in the world.  

    Media Contacts:
    Ryal Curtis                   Richard Hayhurst    
    MMI Public Relations          Schwartz Communications
    (919) 233-6600                +44 208 973 2630   

SOURCE The Hamner Institutes for Health Sciences



SOURCE The Hamner Institutes for Health Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
3. National Institutes of Health Awards More Than $54 Million to Kaiser Permanente to Conduct Health Research
4. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
5. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
6. City of Hope Testing New Communication Link Between Cancer Therapy System and Elekta Electronic Medical Record System
7. Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International
8. Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System
9. US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
10. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
11. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):